Welcome to Allegro Ophthalmics
Accelerated Innovation. Needed Intervention.
With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.
Allegro Vision & Mission
Our vision is truly to ensure that more people keep their vision and do not suffer from blindness.
Allegro’s oligopeptide shows promise with a new mechanism of action for the prevention and management of ophthalmic disorders.